1. Home
  2. AIM vs ICU Comparison

AIM vs ICU Comparison

Compare AIM & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AIM
  • ICU
  • Stock Information
  • Founded
  • AIM 1966
  • ICU 2018
  • Country
  • AIM United States
  • ICU United States
  • Employees
  • AIM N/A
  • ICU N/A
  • Industry
  • AIM Biotechnology: Biological Products (No Diagnostic Substances)
  • ICU Biotechnology: Pharmaceutical Preparations
  • Sector
  • AIM Health Care
  • ICU Health Care
  • Exchange
  • AIM Nasdaq
  • ICU Nasdaq
  • Market Cap
  • AIM 8.8M
  • ICU 10.4M
  • IPO Year
  • AIM N/A
  • ICU N/A
  • Fundamental
  • Price
  • AIM $0.12
  • ICU $1.35
  • Analyst Decision
  • AIM Strong Buy
  • ICU
  • Analyst Count
  • AIM 2
  • ICU 0
  • Target Price
  • AIM $2.75
  • ICU N/A
  • AVG Volume (30 Days)
  • AIM 476.8K
  • ICU 228.5K
  • Earning Date
  • AIM 03-27-2025
  • ICU 03-27-2025
  • Dividend Yield
  • AIM N/A
  • ICU N/A
  • EPS Growth
  • AIM N/A
  • ICU N/A
  • EPS
  • AIM N/A
  • ICU N/A
  • Revenue
  • AIM $170,000.00
  • ICU $135,000.00
  • Revenue This Year
  • AIM N/A
  • ICU N/A
  • Revenue Next Year
  • AIM $1,693.10
  • ICU N/A
  • P/E Ratio
  • AIM N/A
  • ICU N/A
  • Revenue Growth
  • AIM N/A
  • ICU N/A
  • 52 Week Low
  • AIM $0.11
  • ICU $1.33
  • 52 Week High
  • AIM $0.62
  • ICU $20.00
  • Technical
  • Relative Strength Index (RSI)
  • AIM 42.13
  • ICU 32.31
  • Support Level
  • AIM $0.11
  • ICU $1.56
  • Resistance Level
  • AIM $0.16
  • ICU $2.57
  • Average True Range (ATR)
  • AIM 0.01
  • ICU 0.23
  • MACD
  • AIM 0.00
  • ICU -0.09
  • Stochastic Oscillator
  • AIM 5.00
  • ICU 1.61

About AIM AIM ImmunoTech Inc.

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

About ICU SeaStar Medical Holding Corporation

SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.

Share on Social Networks: